Mayne Pharma Group Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Mayne Pharma Group şirketinin toplam hissedar öz sermayesi A$454.2M ve toplam borcu A$31.6M olup, bu da borç-öz sermaye oranını 7% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla A$1.1B ve A$689.0M dir.

Anahtar bilgiler

7.0%

Borç/özkaynak oranı

AU$31.64m

Borç

Faiz karşılama oranı	n/a
Nakit	AU$149.28m
Eşitlik	AU$454.19m
Toplam yükümlülükler	AU$688.99m
Toplam varlıklar	AU$1.14b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: MYX 'nin kısa vadeli varlıkları ( A$460.6M ) kısa vadeli yükümlülüklerini ( A$313.9M ) aşıyor.

Uzun Vadeli Yükümlülükler: MYX şirketinin kısa vadeli varlıkları ( A$460.6M ) uzun vadeli yükümlülüklerini ( A$375.1M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: MYX şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: MYX 'nin borç/öz sermaye oranı son 5 yılda 36.5% seviyesinden 7% seviyesine düştü.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: MYX şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: MYX un, serbest nakit akışı her yıl % 49.3 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Mayne Pharma Group Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

New major risk - Financial position

Full year 2024 earnings released: AU$2.12 loss per share (vs AU$3.86 loss in FY 2023)

No longer forecast to breakeven

New minor risk - Profitability

First half 2024 earnings released: AU$0.88 loss per share (vs AU$1.38 loss in 1H 2023)

Forecast to breakeven in 2026

Mayne Pharma Group Limited to Report Fiscal Year 2024 Results on Aug 23, 2024

Mayne Pharma Group Limited to Report First Half, 2024 Results on Feb 26, 2024

High number of new directors

Mayne Pharma Group Limited Approves Election of Anne Lockwood

Mayne Pharma Group Limited, Annual General Meeting, Nov 30, 2023

Independent Non-Executive Director recently bought AU$69k worth of stock

Full year 2023 earnings released: AU$3.86 loss per share (vs AU$3.20 loss in FY 2022)

New minor risk - Financial data availability

Mayne Pharma Group Limited to Report Fiscal Year 2023 Results on Aug 31, 2023

Mayne Pharma Group Limited Announces Retirement of Carolyn Myers from the Board At the End of July 2023

Independent Non-Executive Chairman recently bought AU$74k worth of stock

First half 2023 earnings released: AU$0.078 loss per share (vs AU$0.62 loss in 1H 2022)

Mayne Pharma Group Limited to Report First Half, 2023 Results on Feb 28, 2023

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces US Launch of Haloette, a Generic Version of Nuvaring

Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Certain Assets of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

High number of new directors

High number of new directors

Mayne Pharma Group Limited Declares Fully Franked Special Dividend, Payable on 27 January 2023

Catalent, Inc. (NYSE:CTLT) acquired Metrics, Inc. from Mayne Pharma Group Limited (ASX:MYX) for approximately $480 million.

Mayne Pharma Group Limited Announces Executive Changes Effective from 1 October 2022

Mayne Pharma Group Limited Announces Management Changes

Full year 2022 earnings released: AU$0.16 loss per share (vs AU$0.13 loss in FY 2021)

Scott Richards Plans to Retire as CEO of Mayne Pharma Group Limited

FDA Grants Approval to Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA of the Abbreviated New Drug Application (Anda) for Haloette

Mayne Pharma Group Limited and Mithra Pharmaceuticals, Sa Announces NEXTSTELLIS Oral Contraceptive Now Available in Australia

Mayne Pharma Group Limited Announces CFO Changes

Forecast breakeven date pushed back to 2024

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Mayne Pharma Expands U.S Dermatology Portfolio

Insufficient new directors

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Therapeutic Goods Administration Approval of NEXTSTELLIS® Oral Contraceptive

High number of new directors

Independent Non Executive Director Bruce Mathieson has left the company

Independent Chairman Roger Corbett has left the company

Independent Chairman Roger Corbett has left the company

U.S. Food and Drug Administration Approves Mayne Pharma LEXETTE for Adolescent Plaque Psoriasis

Forecast to breakeven in 2023

Independent Non-Executive Director recently bought AU$137k worth of stock

Full year 2021 earnings released: AU$0.13 loss per share (vs AU$0.061 loss in FY 2020)

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Nextstellis Receives FDA Marketing Exclusivity and Phase Iii Data Published

Mayne Pharma Announces New Data Showing Treatment with Nextstellis® Investigational Combined Oral Contraceptive (Coc) Containing Drospirenone (Drsp) and Estetrol

Mayne Pharma Group Limited Launches Another Generic Oral Contraceptive

Revenue beats expectations

First half 2021 earnings released: AU$0.12 loss per share (vs AU$0.012 loss in 1H 2020)

Mayne Pharma Group Limited to Report Fiscal Year 2021 Results on Aug 27, 2021

New 90-day low: AU$0.32

Mayne Pharma Group Limited Launches MICROGESTIN 24 FE Tablets in the United States

New 90-day low: AU$0.32

New 90-day low: AU$0.32

Mayne Pharma Group Limited Provides Update on Women's Health Pipeline

Mayne Pharma Group Limited Appoints Peter Paltoglou as Chief Financial Officer

New 90-day low - AU$0.33

New 90-day low - AU$0.34

Full year earnings released

Mayne Pharma Group Limited to Report Fiscal Year 2020 Results on Aug 21, 2020

Mayne Pharma Group Limited(ASX:MYX) dropped from S&P/ASX 200 Index

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin